| Year |
Citation |
Score |
| 2022 |
Okoye AA, Fromentin R, Takata H, Brehm JH, Fukazawa Y, Randall B, Pardons M, Tai V, Tang J, Smedley J, Axthelm M, Lifson JD, Picker LJ, Favre D, Trautmann L, et al. The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. Plos Pathogens. 18: e1010245. PMID 35041707 DOI: 10.1371/journal.ppat.1010245 |
0.397 |
|
| 2020 |
Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, Mattingly C, Ho PT, Schoof N, Cammon CG, Tharp GK, Kanke M, Wang Z, Cleary RA, Upadhyay AA, ... ... Brehm JH, et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature. PMID 31969707 DOI: 10.1038/S41586-020-1951-3 |
0.369 |
|
| 2017 |
Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. Plos Pathogens. 13: e1006740. PMID 29267399 DOI: 10.1371/Journal.Ppat.1006740 |
0.349 |
|
| 2015 |
Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJO, Miller MD, Hazuda DJ, Deeks SG, et al. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals Ebiomedicine. DOI: 10.1016/j.ebiom.2015.06.019 |
0.319 |
|
| 2012 |
Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 737-45. PMID 22618567 DOI: 10.1093/Cid/Cis501 |
0.718 |
|
| 2012 |
Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. Plos One. 7: e31558. PMID 22363673 DOI: 10.1371/Journal.Pone.0031558 |
0.77 |
|
| 2011 |
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. Journal of Acquired Immune Deficiency Syndromes (1999). 56: 344-8. PMID 21350368 DOI: 10.1097/Qai.0B013E31820Cf029 |
0.708 |
|
| 2008 |
Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry. 47: 14020-7. PMID 19067547 DOI: 10.1021/Bi8014778 |
0.68 |
|
| 2007 |
Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. Journal of Virology. 81: 7852-9. PMID 17507476 DOI: 10.1128/Jvi.02203-06 |
0.33 |
|
| Show low-probability matches. |